MX2012007474A - Derivados de 3-hidroxi-5-arilisotiazol novedosos. - Google Patents

Derivados de 3-hidroxi-5-arilisotiazol novedosos.

Info

Publication number
MX2012007474A
MX2012007474A MX2012007474A MX2012007474A MX2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A MX 2012007474 A MX2012007474 A MX 2012007474A
Authority
MX
Mexico
Prior art keywords
ring
novel
arylisothiazole
hydroxy
derivative
Prior art date
Application number
MX2012007474A
Other languages
English (en)
Inventor
Naoto Kosuga
Daido Hotta
Muneyoshi Makabe
Akihiro Okano
Munetaka Ohkouchi
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of MX2012007474A publication Critical patent/MX2012007474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Problema. Proporcionar un agente que activa GPR40 que tiene, como un ingrediente activo, un compuesto novedoso que tiene una acción agonista GPR40, una sal del compuesto, un solvato de la sal o el compuesto, o similares, particularmente, un secretagogo de insulina y y un agente terapéutico y/o profiláctico contra diabetes, obesidad, u otras enfermedades. Medios para solucionar el problema Un compuesto de la Fórmula (I) (ver fórmula (I)) donde n es 0 hasta 2; p es 0 hasta 4; j es 0 hasta 3; k es 0 hasta 2; un anillo A es un grupo arilo que está opcionalmente sustituido con L o un grupo heterocíclico que está opcionalmente sustituido con L; un anillo B es un anillo de benceno, un anillo de piridina, o un anillo de pirimidina; X es O, S, -NR7-; y R1 hasta R7 son grupos específicos, una sal del compuesto, o un solvato de la sal o el compuesto.
MX2012007474A 2009-12-25 2010-12-24 Derivados de 3-hidroxi-5-arilisotiazol novedosos. MX2012007474A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009295855 2009-12-25
JP2010043420 2010-02-26
PCT/JP2010/073464 WO2011078371A1 (ja) 2009-12-25 2010-12-24 新規３－ヒドロキシ－５－アリールイソチアゾール誘導体

Publications (1)

Publication Number Publication Date
MX2012007474A true MX2012007474A (es) 2012-08-01

Family

ID=44195895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007474A MX2012007474A (es) 2009-12-25 2010-12-24 Derivados de 3-hidroxi-5-arilisotiazol novedosos.

Country Status (25)

Country Link
US (1) US8476287B2 (es)
EP (1) EP2518060A4 (es)
JP (2) JP5002077B2 (es)
KR (1) KR20130004262A (es)
CN (2) CN102712610B (es)
AU (1) AU2010336225A1 (es)
BR (1) BR112012015612A2 (es)
CA (1) CA2785674A1 (es)
CL (1) CL2012001722A1 (es)
CO (1) CO6650337A2 (es)
CR (1) CR20120345A (es)
EA (1) EA201290574A1 (es)
EC (1) ECSP12012056A (es)
GT (1) GT201200217A (es)
HN (1) HN2012001351A (es)
IL (1) IL220616A0 (es)
MA (1) MA33952B1 (es)
MX (1) MX2012007474A (es)
NI (1) NI201200113A (es)
NZ (1) NZ601408A (es)
PE (1) PE20121639A1 (es)
RU (1) RU2567755C2 (es)
SG (1) SG181961A1 (es)
WO (1) WO2011078371A1 (es)
ZA (1) ZA201203416B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
US8581584B2 (en) * 2010-05-26 2013-11-12 Florida State University Research Foundation Membrane proteins, mechanisms of action and uses thereof
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
JP5420796B2 (ja) 2011-04-27 2014-02-19 持田製薬株式会社 新規３−ヒドロキシイソチアゾール１−オキシド誘導体
JPWO2012147516A1 (ja) * 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2013154163A1 (ja) * 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
PT2841428T (pt) 2012-04-24 2018-11-29 Vertex Pharma Inibidores de adn-pk
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105814036B (zh) 2013-10-17 2018-10-26 沃泰克斯药物股份有限公司 作为dna-pk抑制剂的共晶
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
RU2701188C2 (ru) * 2015-02-27 2019-09-25 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
CN110066254B (zh) * 2018-11-16 2021-03-19 温州大学 一种异噻唑-3-酮化合物的制备方法
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
CN115433143B (zh) * 2021-06-03 2023-10-13 中国科学院大连化学物理研究所 一种异噻唑啉酮类化合物的合成方法
CN115386028B (zh) * 2022-08-26 2023-06-23 长春理工大学 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562283A (en) 1968-07-01 1971-02-09 Rohm & Haas 1-oxo and 1,1-dioxo-3-isothiazolones
US3801575A (en) * 1972-01-24 1974-04-02 Rohm & Haas 3-hydroxyisothiazoles
AU711927B2 (en) 1996-02-27 1999-10-21 Sankyo Company Limited Isoxazole derivatives
JP2000204077A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
NZ513432A (en) 1999-01-13 2004-02-27 Warner Lambert Co 1-heterocycle substituted diarylamines
WO2004011446A1 (en) 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
CA2497901A1 (en) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
BRPI0418148A (pt) 2003-12-25 2007-04-17 Takeda Pharmaceutical composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
WO2008033931A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
CA2700028A1 (en) 2007-09-21 2009-04-02 Sanofi-Aventis (carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
CA2702047C (en) 2007-10-10 2012-04-17 Amgen Inc. Substituted biphenyl gpr40 modulators
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
NZ584161A (en) 2007-10-26 2011-12-22 Japan Tobacco Inc Spiro-ring compound and use thereof for medical purposes
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US20110065739A1 (en) 2008-06-02 2011-03-17 Makoto Ishikawa Novel isoxazole drivative
EP2289868B1 (en) 2008-06-25 2014-08-13 Daiichi Sankyo Company, Limited Carboxylic acid compound
EP2389226B1 (en) 2009-01-23 2013-11-20 Merck Sharp & Dohme Corp. Bridged and fused heterocyclic antidiabetic compounds
WO2010091176A1 (en) 2009-02-05 2010-08-12 Schering Corporation Phthalazine-containing antidiabetic compounds
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
CN101781268B (zh) * 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体

Also Published As

Publication number Publication date
ECSP12012056A (es) 2012-10-30
WO2011078371A1 (ja) 2011-06-30
GT201200217A (es) 2014-02-10
IL220616A0 (en) 2012-08-30
CR20120345A (es) 2012-11-01
JPWO2011078371A1 (ja) 2013-05-09
EP2518060A4 (en) 2014-01-08
CA2785674A1 (en) 2011-06-30
PE20121639A1 (es) 2012-12-02
CN102712610A (zh) 2012-10-03
US8476287B2 (en) 2013-07-02
HN2012001351A (es) 2015-03-23
SG181961A1 (en) 2012-08-30
NZ601408A (en) 2013-12-20
AU2010336225A1 (en) 2012-08-16
CL2012001722A1 (es) 2012-12-14
US20120157459A1 (en) 2012-06-21
MA33952B1 (fr) 2013-01-02
RU2012131840A (ru) 2014-01-27
BR112012015612A2 (pt) 2016-03-15
CO6650337A2 (es) 2013-04-15
CN102712610B (zh) 2015-03-04
KR20130004262A (ko) 2013-01-09
NI201200113A (es) 2012-08-13
CN104710381A (zh) 2015-06-17
ZA201203416B (en) 2013-08-28
EA201290574A1 (ru) 2012-12-28
JP5002077B2 (ja) 2012-08-15
EP2518060A1 (en) 2012-10-31
JP2012153726A (ja) 2012-08-16
RU2567755C2 (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
MX2012007474A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos.
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
MX2013012798A (es) Compuestos heterociclicos fusionados como moduladores del canal de sodio.
NZ601638A (en) Dihydrofuran derivatives as insecticidal compounds
MX2011008501A (es) Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
MY177250A (en) Novel nicotinamide derivative or salt thereof
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
UA97257C2 (en) Indole derivatives
MY152972A (en) Azabicyclo compound and salt thereof
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
AR076765A1 (es) Compuestos antivirales
MY158982A (en) Heterocyclic compound
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
NZ600837A (en) 1,3,4-oxadiazole-2-carboxamide compound
MX2010008363A (es) Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta.
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
CL2011002181A1 (es) Compuestos ciclicos o heterociclicos (n,o,s) de derivados de fenil (heterociclil) fenil (metil,etil) amina, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso para el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia a la glucosa e hiperlipidemia, entre otras enfermedades.
MY152475A (en) Fused ring compounds and use thereof
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
ECSP11010849A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
MY167569A (en) Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates
MX348979B (es) Agente de control de enfermedades de las plantas.
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.

Legal Events

Date Code Title Description
FG Grant or registration